S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ACXP

Acurx Pharmaceuticals - ACXP Stock Forecast, Price & News

$3.01
-0.13 (-4.14%)
(As of 03/20/2023 08:08 AM ET)
Add
Compare
Today's Range
$3.01
$3.01
50-Day Range
$3.14
$4.25
52-Week Range
$2.33
$4.85
Volume
900 shs
Average Volume
37,160 shs
Market Capitalization
$35.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Acurx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
365.1% Upside
$14.00 Price Target
Short Interest
Healthy
0.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.23mentions of Acurx Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.99) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

544th out of 983 stocks

Pharmaceutical Preparations Industry

252nd out of 480 stocks


ACXP stock logo

About Acurx Pharmaceuticals (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.

Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACXP Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Acurx is Setting a High Bar for New Treatments in C. diff
See More Headlines
Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACXP Company Calendar

Today
3/19/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACXP
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+345.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-12,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.23 per share

Miscellaneous

Free Float
8,011,000
Market Cap
$36.55 million
Optionable
Not Optionable
Beta
-0.92

Key Executives

  • Mr. Robert J. DeLucciaMr. Robert J. DeLuccia (Age 76)
    Co-Founder & Exec. Chairman
    Comp: $464.77k
  • Mr. David P. Luci CPAMr. David P. Luci CPA (Age 55)
    CPA, Esq., J.D., Corp. Sec., Co-Founder, Pres, CEO & Director
    Comp: $443.14k
  • Mr. Robert G. Shawah CPA (Age 55)
    CPA, Co-Founder & CFO
    Comp: $200.34k













ACXP Stock - Frequently Asked Questions

Should I buy or sell Acurx Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACXP shares.
View ACXP analyst ratings
or view top-rated stocks.

What is Acurx Pharmaceuticals' stock price forecast for 2023?

2 equities research analysts have issued 12 month price objectives for Acurx Pharmaceuticals' shares. Their ACXP share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 345.9% from the stock's current price.
View analysts price targets for ACXP
or view top-rated stocks among Wall Street analysts.

How have ACXP shares performed in 2023?

Acurx Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, ACXP shares have decreased by 21.1% and is now trading at $3.14.
View the best growth stocks for 2023 here
.

Are investors shorting Acurx Pharmaceuticals?

Acurx Pharmaceuticals saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 24,900 shares, a drop of 33.8% from the February 13th total of 37,600 shares. Based on an average trading volume of 33,900 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.3% of the company's stock are sold short.
View Acurx Pharmaceuticals' Short Interest
.

When is Acurx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ACXP earnings forecast
.

When did Acurx Pharmaceuticals IPO?

(ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO.

What is Acurx Pharmaceuticals' stock symbol?

Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."

Who are Acurx Pharmaceuticals' major shareholders?

Acurx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.59%), Millennium Management LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia.
View institutional ownership trends
.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acurx Pharmaceuticals' stock price today?

One share of ACXP stock can currently be purchased for approximately $3.14.

How much money does Acurx Pharmaceuticals make?

Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $36.55 million. The company earns $-12,750,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How can I contact Acurx Pharmaceuticals?

The official website for the company is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com.

This page (NASDAQ:ACXP) was last updated on 3/20/2023 by MarketBeat.com Staff